Entrada Therapeutics Inc   (TRDA)
Other Ticker:  
Price: $15.2900 $0.44 2.963%
Day's High: $15.5 Week Perf: -1.35 %
Day's Low: $ 14.54 30 Day Perf: -0.78 %
Volume (M): 17 52 Wk High: $ 24.38
Volume (M$): $ 265 52 Wk Avg: $15.12
Open: $14.89 52 Wk Low: $9.32

 Market Capitalization (Millions $) 507
 Shares Outstanding (Millions) 33
 Employees 89
 Revenues (TTM) (Millions $) 43
 Net Income (TTM) (Millions $) -67
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 5

Entrada Therapeutics Inc
Entrada Therapeutics Inc is a clinical-stage biotechnology company that is dedicated to developing transformative therapeutics for various serious diseases. The company's technology platform is focused on utilizing the body's natural cellular uptake mechanisms to deliver large macromolecules, such as proteins and nucleic acids, across biological barriers for targeted intracellular delivery.

Founded in 2018, Entrada Therapeutics is headquartered in Boston, Massachusetts, in the United States, with additional offices in San Diego, California. The company is led by a team of seasoned industry executives, including CEO Dipal Doshi, President and COO Meghna Dasgupta, and CMO James Hamilton.

The company's lead program, ENTR-101, is a potential treatment for cystic fibrosis. ENTR-101 utilizes Entrada's proprietary Endosomal Escape Vehicle (EEV) technology to transport a specially designed protein that corrects the underlying genetic mutation causing cystic fibrosis. This technology allows the protein to enter the cell, bypass molecular barriers and reach its target in the endosome, thus enabling the protein to be fully functional.

In addition to ENTR-101, Entrada has a robust pipeline that includes multiple therapeutic programs in various stages of development. The company is focused on developing therapies for indications where macromolecular therapeutics have the potential to provide significant patient benefit, such as neurodegenerative diseases, genetic disorders, and cancer.

Entrada Therapeutics has developed strategic collaborations with key partners in the biotech industry, including Roche, Ferring Pharmaceuticals, and BMS. These partnerships provide the company with additional funding and resources, as well as important guidance and expertise.

Overall, Entrada Therapeutics is committed to bringing innovative, life-changing therapies to patients in need, by harnessing the power of its unique technology platform and scientific expertise. Their work is poised to have a profound impact on the lives of patients suffering from serious diseases.

   Company Address: One Design Center Place Boston 2210 MA
   Company Phone Number: 520-9158   Stock Exchange / Ticker: NASDAQ TRDA
   TRDA is expected to report next financial results on November 06, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Renovaro Biosciences Inc

Headline: Renovaro Biosciences Inc Continues to Report Zero Revenue, Reflecting Limited Growth in Q2 Fiscal Year 2023 Pharmaceutical preparations company experiences no change in revenue compared to previous year, raises concerns over lack of expansion prospects.

Renovaro Biosciences Inc, a major pharmaceutical preparations company, has released its financial report for the fiscal period ending June 30, 2023. During this period, the company experienced zero gain per share, an improvement compared to the same period a year ago when it reported a gain of $0.33 per share. It also represents an increase from the preceding financial reporting period when the company reported a loss of $0.08 per share.
In terms of revenue, Renovaro Biosciences Inc did not experience any change compared to the corresponding financial reporting period a year ago. The revenue remained at $0.00 million, and there was no sequential change either. This stability in revenue could be an area of concern for the company, as it suggests a lack of growth or expansion in its operations.

Immuron Limited

Immuron Limited reports decreased revenue and widened net loss in Q4 2023

In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.

Procyon Corporation

Observing the fourth quarter of 2023 numbers, Procyon Corporation reveals concerning revenue decline

Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.

Innovation Pharmaceuticals Inc

Revitalizing Growth: Innovation Pharmaceuticals Inc's Revenue Stagnant, But Positive Signs Emerge

Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.

Palatin Technologies Inc

Palatin Technologies Inc Defies the Odds with Explosive Revenue Growth in Q4 2023, While Major Pharmaceutical Preparations Companies Struggle to Turn Profitable

Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.


Entrada Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com